Inovio Pharmaceuticals, Inc.
INONASDAQHealthcare● Active
$1.13
+$0.04(+3.21%)
Market Cap$60288597
P/E Ratio—
52W High$2.98
52W Low$1.03
Inovio Pharmaceuticals, Inc. (INO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
INO · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.28
Est. -$0.30 · +6.7%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
INO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.28 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.30 | -$0.28 | +6.7% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.37 | $0.31 | +183.8% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.51 | -$0.44 | +13.7% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.63 | -$0.61 | +3.2% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.74 | -$0.51 | +31.1% | $0.00B | $0.00B | +553.4% |
| ▲ Q1 FY2025 | Mar 18, 2025 | -$0.87 | -$0.69 | +20.7% | $0.00B | $0.00B | +134.0% |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$1.20 | -$0.89 | +25.8% | — | $0.00B | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.28
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.28
EPS Est.
-$0.30
EPS Surpr.
+6.7%
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
$0.31
EPS Est.
-$0.37
EPS Surpr.
+183.8%
Revenue
—
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.44
EPS Est.
-$0.51
EPS Surpr.
+13.7%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.61
EPS Est.
-$0.63
EPS Surpr.
+3.2%
Revenue
—
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.51
EPS Est.
-$0.74
EPS Surpr.
+31.1%
Revenue
$0.00B
Q1 FY2025
Mar 18, 2025Beat
EPS Actual
-$0.69
EPS Est.
-$0.87
EPS Surpr.
+20.7%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.89
EPS Est.
-$1.20
EPS Surpr.
+25.8%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q3 FY2027 | $-0.13 | $-0.13 | $-0.13 | 1 |
| Q2 FY2027 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q1 FY2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q4 FY2026 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Q3 FY2026 | $-0.21 | $-0.21 | $-0.21 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +6.7% | $1.41 | $1.34 | -4.96% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +183.8% | $1.69 | $1.68 | -0.59% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +13.7% | $2.12 | $2.15 | +1.42% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +3.2% | $1.44 | $1.49 | +3.47% |
| ▲ Q2 FY2025 | May 13, 2025 | +31.1% | $1.94 | $1.92 | -1.03% |
| ▲ Q1 FY2025 | Mar 18, 2025 | +20.7% | $2.11 | $2.10 | -0.47% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +25.8% | $4.95 | $4.77 | -3.64% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -3.5% | $8.59 | $8.71 | +1.40% |
Q2 FY2026-4.96%
Report Date
May 13, 2026
EPS Beat/Miss
+6.7%
Price Before
$1.41
Price After
$1.34
Q1 FY2026-0.59%
Report Date
Mar 12, 2026
EPS Beat/Miss
+183.8%
Price Before
$1.69
Price After
$1.68
Q4 FY2025+1.42%
Report Date
Nov 10, 2025
EPS Beat/Miss
+13.7%
Price Before
$2.12
Price After
$2.15
Q3 FY2025+3.47%
Report Date
Aug 12, 2025
EPS Beat/Miss
+3.2%
Price Before
$1.44
Price After
$1.49
Q2 FY2025-1.03%
Report Date
May 13, 2025
EPS Beat/Miss
+31.1%
Price Before
$1.94
Price After
$1.92
Q1 FY2025-0.47%
Report Date
Mar 18, 2025
EPS Beat/Miss
+20.7%
Price Before
$2.11
Price After
$2.10
Q4 FY2024-3.64%
Report Date
Nov 14, 2024
EPS Beat/Miss
+25.8%
Price Before
$4.95
Price After
$4.77
Q3 FY2024+1.40%
Report Date
Aug 8, 2024
EPS Beat/Miss
-3.5%
Price Before
$8.59
Price After
$8.71
Avg Beat Reaction-0.83%
Avg Miss Reaction+1.40%
Beat Rate7 / 8 quarters
Largest Move-4.96% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: INO ends December
Inovio Pharmaceuticals, Inc. (INO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.28 — beating the analyst consensus of $-0.30 by +6.7%. INO has beaten EPS estimates for 7 consecutive quarters. The next INO earnings date is expected around September 1, 2026.
Each quarter, investors track INO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
INO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
INO earnings · 5 questionsInovio Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. INO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INO historically reports after market close (AMC).
INO earnings datewhen is INO earningsINO next earnings datewhen does INO report earningsINO earnings calendar
▸ Source: FMP · Inovio Pharmaceuticals, Inc. SEC filings · US GAAP · Inovio Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026